Digestive Health & Gastroenterology Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

This Phase 3 trial is studying the drug Upadacitinib in children aged 2 to 18 who have moderate to severe Crohn's Disease. It aims to find out if the medication is safe and effective for young patients who have not responded well to other treatments like corticosteroids or biologics. Successful results could lead to a new treatment option specifically tailored for children living with this challenging condition.

Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation

This Phase 4 study is investigating whether linaclotide, an oral medication, can help adults with type 2 diabetes who suffer from chronic constipation. Constipation is a common issue for people with diabetes, and improving bowel movement frequency could significantly enhance quality of life. The trial is active in the United States and has enrolled 23 participants so far, providing important insights into managing this condition.

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

This Phase 2 trial compares two oral medications, pioglitazone and empagliflozin, for people who have diabetes related to chronic or recurrent acute pancreatitis. Managing blood sugar levels in this group can be especially difficult, and finding an effective treatment could improve overall health and disease control. The study is currently recruiting in the United States with plans to enroll 40 participants.

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

This Phase 2 study is testing the drug DD01 in overweight or obese patients with metabolic-associated steatotic liver disease (MASLD) or metabolic-associated steatohepatitis (MASH). These liver conditions are linked to fat buildup and inflammation that can lead to serious liver damage. If successful, this treatment could reduce liver fat and improve liver health for people affected by these conditions. The study is active in the United States but not currently recruiting.

EUS-GBD vs Antibiotics for Patients at High Risk for Cholecystectomy

This Phase 3 trial is comparing a new endoscopic gallbladder drainage procedure (EUS-GBD) with standard antibiotic treatment for patients who have mild to moderate acute cholecystitis but are considered very high-risk for gallbladder surgery. The goal is to find a safer and more effective treatment that lowers the chance of gallbladder inflammation returning. The study is recruiting in Hong Kong and aims to enroll 110 patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.